Golf Tourney reaches $2 million contribution in 2016!
Then vs NOW: Ovarian cancer research at a crossroads
"We're at a crossroads. We're benefitting from better understanding of genetics, and better clinical trials."
Watch Dr. Matulonis's research update on You Tube!
For example, The FDA approved the PARP inhibitor olaparib in 2014 for women with advanced and recurrent ovarian cancer who test positive for the BRCA gene mutation.
PARP inhibitors restrict cancer cells’ ability to repair damaged DNA, potentially causing the cancer cells to die. Dr. Matulonis and Dr. Liu have been instrumental in leading clinical trials of olaparib since 2007, including one of the trials that led to FDA approval.
Please continue reading on the "More/Ovarian Cancer Updates" page.
A teacher, beloved companion, mom, and glue of her family,
Joan continues to be cherished by many. She taught in special education teacher in the Natick schools for 17 years before joining the South Middlesex Opportunity Council, and working with women coming out of the Framingham Women’s Prison to help them get their GEDs and a new footing in life. This resulted in the establishment of the Joan H. Brack Adult Learning Center at SMOC, the first endeavor and legacy supported by the foundation which honors her life.
We are grateful to many of you who continue to celebrate Joan's spirit and support the ongoing work of her foundation.